[Long-term evaluation of tiapride in patients with various forms of dyskinesia].
Tiapride, a substituted benzamide derivative having chemical structure similar to sulpiride and metoclopramide, has been demonstrated to be a selective dopamine receptor blocking agent of the central nervous system, especially the D2-receptor. The purpose of present study was to investigate efficacy and safety of Tiapride in patients with various forms of dyskinesia in long-term treatment. Severity of dyskinesia was rated using the Abnormal Involuntary Movement Scale (AIMS) developed by the National Institute of Mental Health (U.S.A.). Rating was made before, on week 1,2 and thereafter at 1 to 2 month interval. Adverse reaction was also checked on severity, onset, course and treatment. In patients with parkinsonism, Hoehn Yahr's Grading was also administered. Based on these recording, overall improvement rating (OIR), overall safety rating (OSR) and usefulness, taken OIR and OSR in combination into account, were evaluated at the end of week 4 and at study completion. The results are summarized as follow; Tiapride was given to 17 patients aged 39 to 81 (average: 62.8) in total, 9 with idiopathic dyskinesia, 5 with Meige's syndrome and 3 with parkinsonism developing dyskinesia induced by L-DOPA. Daily doses were ranged from 50 mg in patients with parkinsonism to 600 mg in those with Meige's syndrome. Administration period was 35 to 748 days (average: 324 days). 1. Overall improvement rating (OIR); OIR showed that Tiapride was "markedly improved" in 3 patients, "moderately improved" in 10 and "slightly improved" in 4 on week 4, increasing up to "markedly improved" in 8, "moderately improved" in 6 and "slightly improved" in 3, respectively at study completion.(ABSTRACT TRUNCATED AT 250 WORDS)